Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Transcriptomic-based molecular classification of ampullary adenocarcinoma.

Xumin Huang¹, Weikang Hu², Yang Wu¹

¹Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China; Pancreas Institute, Nanjing Medical University, Nanjing, 210000, China; Jiangsu Provincial Key Laboratory of Chronic Digestive Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210000, China.

|June 30, 2026

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integration analysis of lncRNA and mRNA expression data identifies DOCK4 as a potential biomarker for elderly osteoporosis.

BMC medical genomics·2024

Same author

A systematic review and meta-analysis of the anti-tumor effects of Paeoniae Radix Rubra in animal models.

Journal of ethnopharmacology·2024

Same author

Resilience conferred by APOE-R136S: a defense bestowed by nature to combat Alzheimer's disease.

Signal transduction and targeted therapy·2024

Same author

Enhanced NMDA receptor pathway and glutamate transmission in the hippocampal dentate gyrus mediate the spatial learning and memory impairment of obese rats.

Pflugers Archiv : European journal of physiology·2024

Same author

Benzodiazepines and mortality: Consideration of potential confounders.

Pain practice : the official journal of World Institute of Pain·2024

Same author

Myxoma with rich blood supply in the left atrium.

Echocardiography (Mount Kisco, N.Y.)·2024

Summary

Ampullary adenocarcinoma (AMPAC) classification is improved by a new transcriptomic-based system (AMS). This system identifies two subtypes, AMS-M and AMS-C, with distinct molecular features and prognostic implications, guiding personalized therapy.

Area of Science:

Oncology
Genomics
Translational Research

Background:

Ampullary adenocarcinoma (AMPAC) is a rare cancer with highly variable outcomes.
Current classification methods lack prognostic accuracy and fail to capture molecular heterogeneity.

Purpose of the Study:

To develop a molecular classification for AMPAC using transcriptomic data.
To understand the molecular drivers of AMPAC heterogeneity and identify therapeutic targets.

Main Methods:

Integrated bulk and single-cell RNA sequencing (scRNA-seq) with clinicopathological data.
Developed a transcriptomic-based molecular subtyping system (AMS) for AMPAC.
Investigated the role of MUC16 in AMPAC progression and chemosensitivity.

Related Experiment Videos

Last Updated: Jul 2, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Main Results:

Introduced the AMS classification with two subtypes: AMS-M (mesenchymal, unfavorable prognosis) and AMS-C (classical, better prognosis).
AMS-M tumors show increased epithelial-mesenchymal transition (EMT) and stromal activation.
MUC16 was identified as a key biomarker overexpressed in AMS-M, and its knockout reversed EMT and improved chemosensitivity.

Conclusions:

The AMS classification provides prognostic and therapeutic insights for AMPAC.
Tumor microenvironment plays a critical role in AMPAC heterogeneity.
MUC16 is a potential therapeutic target for precision oncology in AMPAC.